As previously reported, Stifel analyst Daniel Arias upgraded Danaher (DHR) to Buy from Hold with an unchanged price target of $260, telling ...

Stifel upgraded Danaher (DHR) to Buy from Hold with a $260 price target Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” fourth quarter 2024 investor letter ...

Danaher Corporation DHR has failed to impress investors with its recent operational performance due to weakness across its ...

Shareholders of Danaher would probably like to forget the past six months even happened. The stock dropped 23.9% and now ...

We recently published a list of Why These 15 Big-Cap Stocks Are Plunging So Far in 2025. In this article, we are going to ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

Shares of Danaher Corp. DHR slid 1.28% to $212.07 Friday, on what proved to be an all-around positive trading session for the ...

Danaher Corporation (NYSE:DHR), a global science and technology innovator with a market capitalization of $146 billion, has been navigating a complex landscape of opportunities and challenges in ...

Danaher Corporation DHR has failed to impress investors with its recent operational performance due to weakness across its businesses and high operational expenses. Based in Washington ...

Shares of Danaher Corp. DHR slipped 3.23% to $205.23 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.70% to 5,614.56 and Dow ...